Navigation Links
PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy

ject Muscular Dystrophy (www.parentprojectmd.org).

About PTC124

PTC124 is an orally delivered investigational new drug in Phase 2 clinical development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely halt the translation process, producing a shortened, non- functional protein. PTC124 has restored production of full-length, functional proteins in preclinical genetic disease models harboring nonsense mutations. In Phase 1 clinical trials, PTC124 was generally well tolerated, achieved target plasma concentrations that have been associated with activity in preclinical models and did not induce ribosomal read through of normal stop codons. PTC is currently conducting Phase 2 clinical trials of PTC124 in nonsense-mutation-mediated cystic fibrosis (CF) and Duchenne muscular dystrophy (DMD).

It is estimated that 10% of the cases of CF and 13% of the cases of DMD are due to nonsense mutations. PTC believes that PTC124 is potentially applicable to a broad range of other genetic disorders in which a nonsense mutation is the cause of the disease. The FDA has granted PTC124 Fast-Track designations and Orphan Drug designations for the treatment of CF and DMD due to nonsense mutations. PTC124 has also been granted orphan drug status for the treatment of CF and DMD by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). PTC124's development is supported by grants from the Muscular Dystrophy Association (MDA), Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), Parent Project Muscular Dystrophy (PPMD), FDA's Office of Orphan Products Development (OOPD) and by General Clinical Research Center grants from the National Center for Research Resources (NCRR).

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery and d
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:3/31/2015)... CHICAGO , March 31, 2015 UHC ... evaluated the use of medical devices based on cost ... high-priced physician preference items (PPIs). The study examined utilization ... a hospital,s supply expenses 1 —at 10 academic medical ... peripheral stents, and cardiac valves. The ...
(Date:3/31/2015)... N.Y., March 31, 2015 Uroplasty, Inc. (NASDAQ: ... the completion of their merger. The merger was ... the all-stock combination creates a new medical device ... 1, 2015, Cogentix Medical, Inc. will trade on ... will have its U.S. headquarters in ...
(Date:3/31/2015)... the Honourable Rona Ambrose, Minister of Health, met with ... the Government of Canada,s plan ... roundtable provided an important opportunity for both human and ... roles and responsibilities in addressing AMR. Preserving the effectiveness ... as antimicrobial stewardship) was a key focus of the ...
Breaking Medicine Technology:UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4Government of Canada hosts roundtable discussion to advance Canada's work on antimicrobial resistance 2Government of Canada hosts roundtable discussion to advance Canada's work on antimicrobial resistance 3Government of Canada hosts roundtable discussion to advance Canada's work on antimicrobial resistance 4
... INDIANAPOLIS, April 29, 2011 KPaul Properties LLC today ... Women,s Business Enterprise Division, has awarded it the coveted ... a year after KPaul was awarded the INC Magazine ... After receiving the news, founder and president ...
... Mich., April 29, 2011 Phil Hagerman, president and CEO ... Thornton Leader & Innovator of the Year. The ... University, which co-sponsors the annual award along with Grant Thornton ... and Technology Report. Hagerman was chosen from among 45 ...
Cached Medicine Technology:Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 3
(Date:3/31/2015)... Dr. Parsa Mohebi, founder of Parsa Mohebi Hair Restoration ... forefront of using beard hair to fill in balding ... novelty has now become an absolute option for giving patients the ... do believe that beard to scalp hair transplant can be a ... isn’t as dense as we would like it,” says Dr. Parsa ...
(Date:3/31/2015)... VA (PRWEB) March 31, 2015 ... takes place from April 1-7, the Mesothelioma Applied ... its new prevention program, to complement its existing ... , “As part of the Meso Foundation’s ... extinguish fears of diseases related to asbestos, including ...
(Date:3/31/2015)... Francisco, CA (PRWEB) March 31, 2015 ... their upcoming events. The schedule for April will include ... follows: , New Student Orientation, 9-11 a.m. April 6, ... held in Room D at the Pioneer Square Campus ... & Financial Aid, 12:30-1:30 p.m. April 14, Students will ...
(Date:3/31/2015)... In honor of National Disability ... for buying from a NMEDA QAP certified dealer. ... a nonprofit organization that provides consumer guidance and ... installation of mobility equipment. The organization’s Quality Assurance ... consistently adhere to the highest quality safety and ...
(Date:3/31/2015)... Nashua, NH (PRWEB) March 31, 2015 ... Class of 2015 at Rivier University’s Commencement ... honorary doctorate of humane letters in recognition of her ... educator. , Serving as a front-line caregiver and senior ... for 25 years and advancing to leadership roles, including ...
Breaking Medicine News(10 mins):Health News:Is Beard to Scalp Hair Transplant the Future? 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:ACTCM Announces April Event Schedule 2Health News:Advanced Driving Systems Celebrates National Disability Month 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3
... Maureen Salamon HealthDay Reporter , WEDNESDAY, Jan. 4 ... shown only limited effectiveness in thwarting one type of the ... type from spreading, a new study shows. , , A ... on more than 8,300 women aged 18 to 30 who ...
... 5 (HealthDay News) -- More than half of U.S. jails ... outbreak of H1N1 swine flu, a new study says. ... to infectious diseases. The steady stream of new arrivals can ... confinement makes it easy for diseases to spread, researchers from ...
... play a role in the structural framework of tissues, ... also contribute to melanoma drug resistance and may also ... enhanced following a patient being removed from a targeted ... Fla. Alexander R. Anderson, Ph.D., co-director of ...
... News) -- Worried about the growing threat of ... Administration on Wednesday curbed the use of certain antibiotics ... antibiotics in food-producing animals is thought to be a ... The new ban includes antibiotics known as cephalosporins, ...
... THURSDAY, Jan. 5 (HealthDay News) -- Toddlers who miss daytime ... in life, a new study indicates. Researchers looked at ... depriving them of a single daily nap resulted in more ... abilities. "Many young children today are not getting enough ...
... having high glucose levels in the blood, is ... in hospitalized patients. Today, The Endocrine Society released ... practical and safe glycemic targets and describing protocols ... for hospitalized patients in a non-critical care setting. ...
Cached Medicine News:Health News:Potential Herpes Vaccine Disappoints Researchers 2Health News:Potential Herpes Vaccine Disappoints Researchers 3Health News:Many Jails Got No Flu Shots During H1N1 Outbreak: CDC 2Health News:Fibroblasts contribute to melanoma tumor growth, say Moffitt Cancer Center researchers 2Health News:FDA Curbs Use of Certain Antibiotics in Livestock, Poultry 2Health News:FDA Curbs Use of Certain Antibiotics in Livestock, Poultry 3Health News:Missed Naps Could Put Toddlers at Risk for Mood Disorders 2Health News:Experts suggest all hospitalized patients have blood glucose levels tested 2Health News:Experts suggest all hospitalized patients have blood glucose levels tested 3
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
...
Medicine Products: